<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379025/" ref="ordinalpos=2835&amp;ncbi_uid=7401463&amp;link_uid=PMC4379025" image-link="/pmc/articles/PMC4379025/figure/pone.0119512.g007/" class="imagepopup">Fig 7. Effect of <span class="highlight" style="background-color:">pathway</span> inhibitors in the presence or absence of costunolide on AFP expression and secretion..  From: Telomerase Inhibition Decreases Alpha-Fetoprotein Expression and Secretion by Hepatocellular Carcinoma Cell Lines: In Vitro and In Vivo Study. </a></div><br /><div class="p4l_captionBody">The cells were seeded in a six-well plate at a density of 2x105 cells/well. At 80% confluence, the cells were treated with inhibitors of the PI3k/mTOR/Akt and MAPK/ERK signaling pathways and costunolide for 48 h. The supernatants were then collected and assessed by ELISA. (A) Effect of inhibitors of the PI3K/Akt/mTOR pathway on AFP secretion by HepG2/C3A cells. (B) Effect of inhibitors of the PI3K/Akt/mTOR pathway on AFP secretion by PLC/PRF/5 cells. *P&lt;0.05 versus untreated cells. **P&lt;0.01 versus untreated cells.</div></div>